Off-Label Ozempic Usage Is Fueling Our Culture of Disordered Eating
"We just add another tool to the stockpile of ways to self-destruct with an eating disorder," one doctor told Jezebel.
In Depth 
                            Illustration: Vicky Leta
There’s a new name on the lips of everyone looking to shed their last five, 10, or even 25 pounds. That name is semaglutide.
Better known by its commercial name Ozempic, semaglutide is an injectable antidiabetic medication that curbs hunger and makes food seem unappetizing. A side effect of that diminished appetite is pound shedding, which has led to explosive off-label use for weight loss. (Wegovy, also a semaglutide, is approved by the Food and Drug Administration for weight loss for “overweight” people with a BMI of 27 or 30.) In early 2023, TikTok users posted recipes to help each other mix Ozempic on their own at home. Rumors flew about which Hollywood elites use it for weight loss; professional troll Meghan McCain said she was pressured to take the injectable to lose weight after birthing her second child. A software developer told NBC News that using Ozempic was like a “diet” that helped her drop more than 50 pounds.
Then, on Monday, New York published a feature about how trendy Ozempic and semaglutides generally have become with the headline “Life After Food?” Interviewees reported a severe lack of appetite; one source said they even had to remind themselves to drink water. Another said, “It’s really fun for [already-thin women] to have their jeans hang off of them like they’re a Hadid. There is an addictive quality to it.” An actor described herself as less anxious because she was less hungry, and said Ozempic allowed her “to be casual about food”: “I can just have one bite, or two bites, or three.”
That this feature about no longer wanting to eat came out on the first day of Eating Disorders Awareness Week put the limits of irony to the test.
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
- 
        
        
            
 
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
        